Dose-averaged dose rate better predicts ion-chamber recombination in UHDR particle beams
In synchrotron UHDR proton and carbon-ion beams, dose-averaged dose rate better described chamber recombination than conventional field-averaged metrics.
In synchrotron UHDR proton and carbon-ion beams, dose-averaged dose rate better described chamber recombination than conventional field-averaged metrics.
AAPM MPPG 18.a sets daily output constancy at ±3%, annual field alignment at ±2 mm, and physicist-led commissioning requirements for superficial RT.
In 33 right-sided breast RT patients, larger target dimensions correlated with higher ipsilateral lung and cardiac doses, but proposed thresholds remain unvalidated.
In ten head and neck cancer plans, proton arc therapy reduced simulated mean circulating blood dose from 0.563 to 0.483 Gy(RBE).
In 41 coronary CT angiograms, ultra-high-resolution imaging improved image quality but delivered 26.4 mSv versus 1.4 mSv with Flash acquisition.
Across more than 20,000 evaluated plans, integrated dose calculation, log-file and portal dosimetry methods identified complementary planning and delivery errors.
Across three electrometers, user-derived calibration factors remained stable over 28 months, with negligible drift-related uncertainty and consistent results across input methods.
Postoperative bowel dysfunction correlated most strongly with high-dose exposure to the internal anal sphincter and puborectalis complex.
Detected Cherenkov signal per dose fell sharply in small fields, driven mainly by optical transport rather than major changes in intrinsic Cherenkov production.
Smaller modular superficial brachytherapy applicators and sequential placement substantially improved dose uniformity, especially for beta-emitting sources.
Modern dosimetry can meet historical accuracy requirements, but tighter geometric precision and particle-specific uncertainties increasingly determine treatment accuracy.
CyberKnife best contained low-dose spread at high lesion burdens but required substantially longer treatment than faster VMAT strategies.
Each 1-Gy increase in estimated immune-cell dose was associated with 66% higher breast cancer mortality after multivariable adjustment.
The unshielded SunSILICON detector required only modest corrections in small fields, while the shielded version became unreliable below approximately 2 cm.
A 1 cm high-density bolus overcame 6 MV photon build-up, but a 2 cm air gap reduced small-field skin dose by 21%.